Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites

Atsushi Goto · Shuji Terai · Munetaka Nakamura · Masaharu Matsumoto · Isao Sakaida

Abstract Tolvaptan is a new drug used for treating ascites induced by liver cirrhosis, and it is covered by health insurance in Japan. In the present report, we describe the case of a 74-year-old man with type C liver cirrhosis and refractory ascites. He was receiving furosemide and spironolactone daily, but still required repeat puncture for ascites removal. Administration of tolvaptan (3.75 mg/day) was started in addition to his existing medications, and was subsequently increased to 7.5 mg/day. However, after 2 months, the ascites again exacerbated. Nevertheless, after we discontinued the administration of furosemide, the tolvaptan became effective. This may be because furosemide administration decreases urine osmolality, resulting in a non-response to tolvaptan.

Keywords Tolvaptan · Vasopressin V2-receptor antagonist · Liver cirrhosis · Refractory ascites · Urine osmolality

Case report

A 74-year-old man presented to our hospital with abdominal pain and bloating since December 2013. He had undergone craniotomy for a brain tumor approximately 30 years ago. He had no history of alcohol consumption or cigarette smoking, and his family history was not significant. Since 2001, he had been managed regularly for type C liver cirrhosis. He did not have a treatment history of interferon use. He had undergone sclerotherapy for esophageal varices in 2001 and hepatic arterial chemoembolization in 2004, and did not have any recurrences. However, he continued to receive oral furosemide (20 mg) and spironolactone (50 mg) daily for ascites retention. Although he maintained a body weight of 60 kg and an abdominal circumference of 85 cm, his body weight and abdominal circumference rapidly increased to 70 kg and 100 cm, respectively. Ultrasound confirmed the presence
of increased ascites; thus, the dose of furosemide was increased to 30 mg/day, and puncture was repeated for ascites removal. Since there was no improvement, he was hospitalized in January 2014.

On admission, the following physical findings were noted: height, 168 cm; body weight, 69 kg; abdominal circumference, 100 cm; consciousness, lucid; body temperature, 35.5 °C; blood pressure, 137/85 mmHg; pulse, 80 beats/min (regular). The palpebral conjunctiva showed no sign of anemia. The bulbar conjunctiva had no yellow staining. The chest findings were normal with no evidence of heart murmur or spider angioma. The abdomen was swollen, severely distended, and wave-pulpable. He had spontaneous abdominal pain without tenderness and had no edema in the extremities.

His blood test findings are shown in Table 1. The Child–Pugh score was 9 points (B) with moderate or greater ascites volume and no encephalopathy. His platelet count was low. No renal impairment was observed.

On plain abdominal computed tomography (Fig. 1), both the hepatic lobes were atrophic with a blunt margin and irregularity on the surface. A moderate volume of ascites retention was observed.

The ascites fluid obtained following puncture indicated the presence of transudative ascites, which was macroscopically pale yellow and transparent with a cell count of 200/μL and a protein level of 2.0 g/dL. The cytological diagnosis was class I, and the culture test was negative.

The patient’s clinical course is presented in Fig. 2. The patient was on salt restriction (<5 g/day) and water restriction (<1 L/day), and he underwent three courses of cell-free and concentrated ascites reinfusion therapy (CART). However, he again exhibited ascites retention after several days, and the urinary volume was insufficient at 1,000–1,500 mL/day. On day 10, oral tolvaptan (3.75 mg/day) was started, and his urinary volume immediately increased to 2,000 mL/day. Adverse reactions, such as hypernatremia and liver dysfunction, were not observed.

Since the patient still required puncture for ascites removal, the dose of tolvaptan was increased to 7.5 mg/day on day 17. His urinary volume increased to approximately 2,500 mL/day, and his body weight and abdominal circumference improved gradually without any puncture for ascites removal. His abdominal pain and bloating improved, and he was discharged on day 22.

He continued tolvaptan (7.5 mg/day) treatment, and at approximately day 60, the patient realized that his urinary volume had decreased. He presented with abdominal bloating and weight gain again. Re-exacerbation of the ascites was suspected, and the patient was readmitted on day 72 (Fig. 3). A sufficient urinary volume was not observed after admission. We presumed that urine osmolality decreased due to the continuous administration of furosemide, which may have hampered the diuretic effect of tolvaptan in the renal collecting tubule; furosemide was discontinued on day 78. Subsequently, his urinary volume temporarily increased to more than 4,000 mL/day. There is a possibility that the albumin infusions (days 78–80) affected the temporary increase in his urinary volume; however, a

| Biochemistry | Hematology |
|--------------|------------|
| TP 6.8 mg/dL | WBC 1,800/μL |
| ALB 2.4 mg/dL | RBC 357 × 10³/μL |
| T-bil 1.30 mg/dL | Hb 12.2 g/dL |
| D-bil 0.35 mg/dL | Plt 4.0 × 10³/μL |
| AST 64 IU/L | Virus marker |
| ALT 60 IU/L | HBs Ag (-) |
| ALP 311 IU/L | HCV Ab (+) |
| γ-GTP 28 IU/L | Urine examination |
| BUN 11.0 mg/dL | Specific gravity 1.010 |
| Cre 0.81 mg/dL | pH 6.5 |
| Na 144 mEq/L | Protein (-) |
| K 2.9 mEq/L | Glucose (-) |
| Cl 108 mEq/L | Occult blood (-) |
| eGFR 71 mL/min/1.73 m² | Ketone (-) |
| Coagulation | Urobilinogen Normal |
| PT 70.3 % | Bilirubin (-) |

TP total protein, ALB albumin, T-bil total bilirubin, D-bil direct bilirubin, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, γ-GTP gamma-glutamyl transpeptidase, BUN blood urea nitrogen, Cre creatinine, Na sodium, K potassium, CI chloride, eGFR estimated glomerular filtration rate, PT prothrombin time, WBC white blood cells, RBC red blood cells, Hb hemoglobin, Plt platelets, HBs Ag hepatitis B core antigen, HCV Ab hepatitis C virus core antigen
volume of ≥2,000 mL/day was maintained over the next month after discontinuing furosemide. The urine osmolality immediately increased from 300 to 650 mOsm/L after discontinuing furosemide. In addition, 3 days after discontinuing furosemide (day 81), the urine osmolality decreased to 365 mOsm/L. The abdominal symptoms, body weight, and abdominal circumference returned to their original levels. Tolvaptan was continued (7.5 mg/day) without exacerbation of the ascites. The serum sodium level was maintained (range 139–144 mEq/L) throughout the course.
Discussion

The use of existing natriuretic agents for treating ascites associated with liver cirrhosis is problematic for the following reasons: hyponatremia is likely to occur; diuresis resistance or impaired renal function is induced by the activation of the renin–angiotensin–aldosterone system; and hypoalbuminemia-associated treatment resistance may occur. Tolvaptan acts on the renal collecting tubule, inhibits the reabsorption of water, and accelerates urinary excretion [1]. Since it results in the excretion of only free water without inducing natriuresis, tolvaptan improves hyponatremia [2]. Moreover, it does not affect the activation of the renin–angiotensin–aldosterone system, thereby allowing the body fluid to be controlled without impairing renal function [3]. According to Japanese and overseas large-scale clinical studies, it exhibits a diuretic effect and improves clinical symptoms in heart failure patients [4, 5].

Thuluvath et al. [6] reported that the administration of a vasopressin V2-receptor antagonist in addition to conventional treatment with furosemide and spironolactone increased urinary volume in liver cirrhosis patients. Okita et al. [7] first reported the results of a randomized, double-blind, placebo-controlled study on tolvaptan for refractory ascites associated with liver cirrhosis. When tolvaptan was administered to patients with hepatic edema at dosages of 30, 15, or 7.5 mg/day for 7 days, the maximum decrease in weight and abdominal circumference was observed in patients receiving 7.5 mg/day, thus providing the basis for the current upper dose limit in the present case. Sakaida et al. [8] reported that the weight loss obtained by short-term treatment with diuretics in liver cirrhosis patients strongly correlated with the volume of ascites, accounting for approximately 30% of cases with weight loss. Moreover, in a randomized, double-blind, placebo-controlled study, they reported that a significant weight loss was obtained in patients receiving 7.5 mg/day of tolvaptan, revealing that it is effective for improving ascites [9]. They also reported that it is useful for treating patients with hypoalbuminemia (serum albumin level <2.5 g/dL), because of tolvaptan’s effect on the renal collecting tubule through the blood flow.

Although tolvaptan is expected to play an innovative role in treating refractory patients, no diuresis is achieved even after administration, and the efficacy of this drug can often be diminished, as seen in the present case. An approach to determine its appropriate use involves the elucidation of the responders to this drug. One possible approach is to use urine osmolality as a marker reflecting the function and activity of the renal collecting tubule. Imamura et al. [10] defined patients with heart failure who had an increase in urinary volume during 24 h after the start of tolvaptan administration as responders, revealing that responders showed a significant improvement in body weight, brain natriuretic peptide levels, and clinical symptoms. Moreover, they reported that the predictive factors of responders are urine osmolality of ≥352 mOsm/L before tolvaptan administration or a ≥26% urine osmolality reduction at 4–6 h after administration [11–13].

The mechanism of water reabsorption by vasopressin is as follows: the binding of vasopressin to V2-receptors in the renal collecting tubule induces cyclic adenosine monophosphate dependent synthesis of the aquaporin-2 water channel and its migration to the cellular surface, which in turn leads to increased water permeability in the collecting tubule, thus resulting in enhanced water reabsorption mediated by an osmotic pressure gradient formed between the hypotonic urine in the collecting tubule and the hypertonic renal interstitium [14]. Tolvaptan competitively inhibits V2-receptor binding, thereby suppressing the expression of aquaporin-2 and inducing water diuresis. Patients who initially have a low urine osmolality may have a decreased expression of aquaporin-2 or a reduced osmotic pressure gradient, thus making it difficult for tolvaptan to be efficacious [11].

The urine osmolality increased from 300 to 650 mOsm/L after discontinuing furosemide in our patient. The urine osmolality should be evaluated before starting tolvaptan. Although the urine osmolality was originally at the level where an effective water diuretic effect could not be obtained, discontinuing furosemide may have increased urine osmolality in the medullary collecting tubule to the range where tolvaptan is effective, thereby achieving diuresis. In addition, 3 days after discontinuing furosemide, the urine osmolality decreased to 365 mOsm/L; thus, the urine osmolality may have decreased because of the sufficient water diuresis caused by tolvaptan. Since the maximum dose of tolvaptan has already been used, it is important to review its preparation by evaluating the osmolality of concomitant diuretic agents.

Our case is valuable, because a non-responder became a responder by adjusting a loop diuretic. The maximum dose of tolvaptan is 7.5 mg/day. However, if 7.5 mg of tolvaptan is administered and the patient’s urine volume decreases, the doctor may assume that this effect is a result of another diuretic. In our case, furosemide decreased the osmolality; therefore, we recommend that clinicians assess the osmolality and reconsider the decreasing effect of other diuretics. Similarly, Imamura et al. [15] reported that a patient with acute renal impairment did not respond to the initial administration but responded to tolvaptan when the renal impairment resolved and renal osmolality was increased. The diuretic effect of tolvaptan can be enhanced by considering the administration timing and by adjusting concomitant conventional diuretic agents. Although the appropriate dosing period for tolvaptan in patients with
hepatic edema is unclear, there is a potential diminished effect after long-term administration. A future study on long-term users is needed to establish the efficacy of tolvaptan.

Disclosures

Conflict of Interest: Isao Sakaida and Shuji Terai received a lecture fee from Otsuka Pharmaceutical Company, which manufactures tolvaptan.

Human/Animal Rights: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).

Informed Consent: Informed consent was obtained from all patients for being included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.
2. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.
3. Miyazaki T, Fujiki H, Yamamura Y, et al. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist—pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25:1–13.
4. Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25:S33–45.
5. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–43.
6. Thuluvath PJ, Maheshwari A, Wong F, et al. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther. 2006;24:973–82.
7. Okita K, Kawazoe S, Hasebe C, et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:83–91.
8. Sakaida I, Okita K. Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy. Hepatol Res. 2013;44:735–9.
9. Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73–82.
10. Imamura T, Kinugawa K, Minatsuji S, et al. Tolvaptan can improve clinical course in responders. Int Heart J. 2013;54:377–81.
11. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients—association between non-responders and chronic kidney disease. Circ J. 2013;77:397–404.
12. Imamura T, Kinugawa K, Minatsuji S, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J. 2013;77:1208–13.
13. Dohi K, Watanabe K, Ito M. Urine osmolality-guided tolvaptan therapy in decompensated heart failure. Circ J. 2013;77:313–4.
14. Deen PM, Knoers NV. Physiology and pathophysiology of the aquaporin-2 water channel. Curr Opin Nephrol Hypertens. 1998;7:37–42.
15. Imamura T, Kinugawa K, Kato N, et al. A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality. Int Heart J. 2013;54:115–8.